Dapagliflozin

1. Dapagliflozin decreases systolic blood pressure in humans.

   Reviewacross clinical studies

   Efficacy and mechanistic insights of dapagliflozin in hypertension management · Clinical and experimental hypertension (New York, N.Y. : 1993) · 2 Oct 2026

1. Dapagliflozin decreases blood pressure in humans.

   Reviewin patients with hypertension and concomitant T2D, CKD, or HF

   Efficacy and mechanistic insights of dapagliflozin in hypertension management · Clinical and experimental hypertension (New York, N.Y. : 1993) · 2 Oct 2026

1. Dapagliflozin decreases renal clearance of TMAO in humans (22.6% lower, p = 0.025).

   Human trialType 2 diabetesn = 54

   Effects of SGLT-2 Inhibitors on Plasma Concentrations and Renal Clearance of the Risk Marker Trimethylamine-N-Oxide in Patients With Type-2 Diabetes · Endocrinology, diabetes & metabolism · 1 Oct 2026

Renal clearance of TMAO →

1. Dapagliflozin increases trimethylamine n-oxide in humans (23.4% higher, p = 0.021).

   Human trialType 2 diabetesn = 54

   Effects of SGLT-2 Inhibitors on Plasma Concentrations and Renal Clearance of the Risk Marker Trimethylamine-N-Oxide in Patients With Type-2 Diabetes · Endocrinology, diabetes & metabolism · 1 Oct 2026

Trimethylamine n-oxide →

1. Dapagliflozin decreases HbA1c in humans.

   Humanscompared with combination therapy with semaglutide6 months

   Dapagliflozin Alone or Combined With Semaglutide: Cardiovascular and Renal Outcomes Among Patients With Type 2 Diabetes Mellitus in a 6-Month Real-World Retrospective Cohort Study in Saudi Arabia · Journal of the ASEAN Federation of Endocrine Societies · 13 Aug 2026

HbA1c →

1. Dapagliflozin improves histological endpoints of MASH in humans.

   Reviewin the DEAN trial

   Dapagliflozin in Metabolic Dysfunction-Associated Steatotic Liver Disease: Clinical Evidence and Therapeutic Potential · Euroasian journal of hepato-gastroenterology · 1 Jan 2026

1. Dapagliflozin decreases hepatic fat in humans.

   Reviewin MASLD / MASH

   Dapagliflozin in Metabolic Dysfunction-Associated Steatotic Liver Disease: Clinical Evidence and Therapeutic Potential · Euroasian journal of hepato-gastroenterology · 1 Jan 2026